Combination therapy with anti-PD-1 antibody, radiotherapy, and tyrosine kinase inhibitor for unresectable primary ectopic hepatocellular carcinoma: a case report with genomic profiling and literature review.

Lenvima (lenvatinib) - Eisai, Merck (MSD)

AiRuiKa (camrelizumab) - Elevar Therapeutics

http://www.ncbi.nlm.nih.gov/pubmed/42523995

Jiaxin Li; Jin Zhou; Mingheng Liao; Peng Tang; Weixing Liu; Xin Wang; Yating Xu; Yixiao Li; Yong Zeng; You Long

Jul 30, 2026